( ADRO ) Strategic partners include Janssen Biotech,Novartis.,J&J
GVAX Pancreas is an important synergistic combination candidate because it is designed to induce T-cells against an array of pancreatic cancer antigens and enable a broad-based immune response and has demonstrated a favorable safety profile in clinical trials to date. ADRO expects to report top-line results from ECLIPSE in the first half of 2016.
In addition, ADRO is evaluating CRS-207 in combination with chemotherapy in unresectable malignanpleural mesothelioma and has a planned study of CRS-207 in combination with GVAX Pancreas and an anti-PD-1 checkpoint inhibitor in metastatic pancreatic cancer.
I'm a player bought
Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles In Value On IPO Debut
Under the collaboration Merck Serono (MKGAY.PK) will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreement with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug (IND) stage, the programs will be transferred to Merck Serono for clinical development and commercialization
Market Research Media
Cyber Security Market for 2015 -cumulative market valued at $65.5 billion
PRX002 is a monoclonal antibody for the potential treatment of Parkinson's disease and other related synucleinopathies. The drug is the focus of a worldwide collaboration between Prothena and Roche.
in ACAD short and CLDN LONG. Heart Medication $100 + Up From here not going to be $24's LOL
EYES Approved Treatment Healthcare Centers Throughout the US and Europe.
Second Sight's Euro MomentumBy: Dallas SalazarMar. 2, 2015 8:02 AM ET | About: Second Sight Medical Products (EYES)